Viagra Connect To Launch In Ireland Following Rx-to-OTC Switch

Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.

Ireland flag in the focus. Europe map with countries flags. Shallow depth of field 3d illustration rendering isolated on white background - Illustration
Ireland follows the UK in approving OTC Viagra Connect • Source: Shutterstock

Viatris – the company created by the merger of Pfizer’s Upjohn and Mylan – is preparing to launch a non-prescription version of its erectile dysfunction treatment Viagra in Ireland following the Rx-to-OTC switch of the drug in the country.

Viagra Connect (50 mg sildenafil) will be available to men aged 18 years and above in Irish pharmacies from “early...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

AESGP Annual Meeting: Commission Must ‘Think Carefully’ Before Reverse-Switching Antimicrobials

 
• By 

If the European Commission is serious about improving the competitiveness of the European Union, it should ditch the idea of making commonly used OTC antimicrobials like thrush treatments and cold sore creams prescription-only, warns Greek Medicines Agency president Evangelos Manolopoulos

Over The Counter: Driving Innovation In France’s Self-Care Market, With NèreS’ Luc Besançon

 
• By 

HBW Insight speaks to NèreS' executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By 

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.

More from Health

Stada Held Back By Weak Cough & Cold Season

 
• By 

While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.

AESGP Annual Meeting: Wastewater Directive Impact Assessment ‘Fundamentally Flawed’

 
• By 

AESGP president Jonathan Workman opens the 61st Annual Meeting with calls for industry unity in the face of the problematic revised EU Urban Wastewater Treatment Directive.

Over The Counter: Driving Innovation In France’s Self-Care Market, With NèreS’ Luc Besançon

 
• By 

HBW Insight speaks to NèreS' executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive.